TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs
TScan Therapeutics announced a 30% workforce reduction, eliminating approximately 66 positions, as part of a plan to save $45 million and extend their cash runway into the second half of 20271.
This layoff represents the company's second round of cuts in 2025, with money redirected to focus on pivotal trials for TSC-101 in leukemia and myelodysplastic syndromes, while pausing a Phase I solid tumor trial1.
Iovance Biotherapeutics is reducing its workforce by about 19% after slower-than-anticipated commercial uptake of Amtagvi, its tumor-infiltrating lymphocyte (TIL) cell therapy for advanced melanoma456.
These restructuring efforts at Iovance are attributed to challenging launch dynamics, including complex manufacturing and logistics for Amtagvi26.
Despite workforce reductions, Iovance is actively advancing development of Amtagvi, which recently showed promise with a 61% response rate in third-line melanoma patients and is also being studied for lung cancer indications810.
The actions at both companies reflect broader industry trends in 2025, where biotech firms are trimming positions to conserve cash, streamline pipelines, and address slower-than-expected product launches or clinical setbacks313.
Sources:
1. https://www.biospace.com/biospace-layoff-tracker
2. https://trial.medpath.com/news/cded4ae131cb86a5/iovance-biotherapeutics-cuts-workforce-by-nearly-20-following-slow-amtagvi-cell-therapy-launch
3. https://www.biopharminternational.com/view/what-sareptas-layoffs-and-others-across-biopharma-mean-for-industry-professionals
4. https://pharmaphorum.com/news/iovance-cuts-staff-slower-cell-therapy-sales-growth
5. https://xtalks.com/pharma-and-biotech-layoffs-2025-4110/
6. https://firstwordpharma.com/story/5987593
8. https://www.quiverquant.com/news/Iovance+Biotherapeutics+Reports+61%25+Response+Rate+for+Amtagvi%C2%AE+in+Third-Line+Melanoma+Patients
10. https://www.bigpharmasharma.com/p/a-til-ing-odyssey-finally-ends-in